- Home
- » Tags
- » Adoptive cell transfer
Top View
- T-Cell–Based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition Roch Houot1,2, Liora Michal Schultz3, Aurelien Marabelle4, and Holbrook Kohrt5
- IL-12-Secreting CD19-Targeted Cord Blood-Derived T Cells for the Immunotherapy of B-Cell Acute Lymphoblastic Leukemia
- Therapy Implications for Adoptive Cell Transfer Gastrointestinal Cancers and Melanoma
- Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19
- Policy 8.01.01 Adoptive Immunotherapy
- The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors
- CAR T-Cell Therapy a New Era in Cancer Treatment
- T-Cell Delivery of Interleukin-12 to the Tumor Microenvironment Triggers Potent Endogenous Anti-Tumor Responses
- Adoptive Immunotherapy Beyond CAR T-Cells
- The Past, Present, and Future of Adoptive T Cell Therapy
- Principles of Adoptive T Cell Therapy in Cancer
- T-Cell Receptor-Based Therapy, Human Leukocyte Antigen Typing, Biomarker Screening, Lymphodepletion, Clinical Trials, Solid Tumors
- Adoptive Immunotherapy CAR-T Cell Therapy: KYMRIAH OR
- Understanding the Characteristics of Tumor-Infiltrating Immune Cells And
- Application of CAR-T Cell Therapy Beyond Oncology: Autoimmune Diseases and Viral Infections
- Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells
- Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
- CAR-T Cell Therapy: Past Successes and Future Challenges